Browsing Tag
Gilead Sciences
52 posts
Gilead gets Trodelvy FDA priority review for pre-treated HR+/HER2- metastatic breast cancer
Gilead Sciences said that Trodelvy (sacituzumab govitecan-hziy) has been granted priority review from the US Food and Drug…
Gilead Sciences to acquire British biotech company MiroBio for $405m
Gilead Sciences has agreed to acquire MiroBio, a clinical-stage British biotech company, in an all-cash deal worth around…
Gilead Sciences gets Veklury FDA approval for non-hospitalized Covid-19 patients
Gilead Sciences has secured expedited approval from the US Food and Drug Administration (FDA) for its nucleotide analog…
Lupin secures FDA approval for generic Truvada, expanding HIV treatment and prevention portfolio in the US
Lupin secures US FDA approval for its generic version of Truvada, targeting HIV treatment and prevention. See what this means for the $2.1B US market.
Cadila Healthcare to bring Black Fungus drug AmphoTLC to India
Cadila Healthcare (also known as Zydus Cadila) has signed a license supply and commercialization agreement with Taiwanese pharma…
Gilead Sciences acquisition of MYR: A strategic move to tackle hepatitis delta virus
In a strategic acquisition aimed at expanding its hepatitis treatment portfolio, US biopharmaceutical giant Gilead Sciences has announced…
Gilead Sciences completes $21bn acquisition of Immunomedics: A new era in cancer treatment
Gilead Sciences, a leading US-based pharmaceutical giant, has successfully concluded its $21 billion acquisition of Immunomedics, a New…
Remdesivir FDA approval: A milestone in the fight against COVID-19
In a significant development for the medical and pharmaceutical communities, Gilead Sciences, a California-based biopharmaceutical company, has received…
Gilead, Galapagos bag Jyseleca EC approval for rheumatoid arthritis
Jyseleca EC approval : Gilead Sciences and Galapagos have secured marketing authorization for Jyseleca (filgotinib 200 mg and…
Gilead acquisition of Immunomedics : Pharma giant to gain access to breast cancer drug Trodelvy
Gilead acquisition of Immunomedics : US pharma giant Gilead Sciences has signed a $21 billion worth deal to…